News | December 03, 2007

Drug-Eluting Stents Improve Patient Outcomes in Routine Practice

December 4, 2007 - In general, drug-eluting stents (DES) achieve better results than bare-metal stents do, U.S. researchers report in the November 20 issue of the Journal of the American College of Cardiology.

"We found that DES, as they are being used in clinical practice in North America, significantly reduce the need for target vessel revascularization compared to bare-metal stents," lead investigator J. Dawn Abbott, M.D., told Reuters Health.

"Importantly," she added, this reduction "was observed in patients with and without complex coronary lesion types."

Dr. Abbott of Rhode Island Hospital, Providence, and colleagues studied data from 2004 for 1460 patients who received at least one DES. These data were compared with earlier records for 1,763 patients who received at least one bare-metal stent.

At one year, the cumulative death and myocardial infarction rate was 7.6 percent in DES patients and 8.7 percent in bare-metal stent patients, a nonsignificant difference. The corresponding rate of target vessel revascularization at one year was 5.0 percent and 9.2 percent (p

In DES patients, the one-year hazard ratio for any repeat vascularization by percutaneous coronary intervention or coronary bypass was 0.38, and the rate of stent thrombosis was 1 percent.

"These improved outcomes," continued Dr. Abbott, "were achieved without any evidence of increased hazard from DES use, as demonstrated by similar one-year rates of death and myocardial infarction, and a very low rate of angiographically confirmed late stent thrombosis."

"While these results certainly confirm the efficacy of DES," she concluded, "we will need longer follow-up to evaluate the incidence of very late stent thrombosis in these patients."

In an accompanying editorial, Franz-Josef Neumann, M.D., Herz-Zentrum, Bad Krozingen, Germany writes that the "mounting evidence on this matter confirms the superior efficacy of DES with respect to the prevention of repeat revascularization and does not suggest inferior safety compared with bare-metal stents."

Ref: J Am Coll Cardiol 2007;50:2029-2038
Source: Reuters Health, December 3, 2007

For more information: www.acc.org

Related Content

Abbott Initiates XIENCE Short DAPT Clinical Trial
News | Antiplatelet and Anticoagulation Therapies| August 03, 2017
Abbott recently announced the first patient has been enrolled in a clinical study evaluating the short-term use of...
Onyx DES 2.0 mm stent meets primary endpoints in small vessels
News | June 12, 2017
June 12, 2017 – The Medtronic Resolute Onyx Drug-Eluting Stent (DES) met its primary endpoint of target lesion failur
First Pennsylvania Patient Treated in LEADERS FREE II Trial of BioFreedom Drug-Coated Stent
News | Stents Drug Eluting| May 12, 2017
PinnacleHealth CardioVascular Institute enrolled the first patient in Pennsylvania in a trial assessing the safety and...
Resolute Onyx DES, drug eluting stent, medtronic, gains FDA approval
Technology | Stents Drug Eluting| May 01, 2017
May 1, 2017 — The U.S.
Sponsored Content | Videos | Stents Drug Eluting| May 01, 2017
This video, provided by Medtronic, demonstrates the Resolute Onyx coronary stent.
Biosensors, BioFreedom drug-coated stent, LEADERS FREE II IDE trial, first patient, U.S. pivotal study
News | Stents Drug Eluting| March 03, 2017
Biosensors International Group Ltd. announced in February enrollment of the first patient in LEADERS FREE II, its new...
CeloNova Cobra Pzf stent
Technology | Stents| March 02, 2017
March 2, 2017 — The U.S. Food and Drug Administration (FDA) cleared CeloNova BioSciences Inc.
Synergy stent, abluminal polymer DES, bioresorbable polymer DES, bioresorbable polymer metallic stent

The Synergy stent is the first FDA cleared drug-eluting stent to use a bioresorbable polymer drug carrier. When the polymer dissolves after about four months, the devices become a bare metal stent. The technology is supposed to reduce the rate of late stent thrombosis due to vessel inflammation caused by durable polymers.

Feature | Stents Bioresorbable| January 17, 2017 | Dave Fornell
One of the big advancements in drug-eluting stent (DES) technology has been the development of bioresorbable polymers
OCT, intravascular imaging, stent, good stent apposition on vessel wall, TRANSFORM-OCT study

An OCT image showing good stent strut apposition against the vessel wall.

News | Stents| January 13, 2017
January 13, 2017 — Results from TRANSFORM-OCT, a prospective, randomized trial using optical coherence tomography (OC
EXCEL Trial, TCT 2016, drug-eluting stents, CABG, surgery left main heart disease, LMCAD

Gregg W. Stone, M.D., presenting the EXCEL data at TCT 2016 during a standing room only late-breaking trial session.

Feature | Stents| January 12, 2017 | Dave Fornell
The biggest news from the 2016 Transcatheter Cardiovascular Therapeutics (TCT) meeting this past fall was the results
Overlay Init